Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

NCT05239624 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: Enfortumab vedotin
DRUG: Pembrolizumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]